Lenimen Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 04-12-2024
- Paid Up Capital ₹ 0.10 M
as on 04-12-2024
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 45.89%
(FY 2022)
- Profit 12.03%
(FY 2022)
- Ebitda 603.61%
(FY 2022)
- Net Worth 32.13%
(FY 2022)
- Total Assets -18.03%
(FY 2022)
About Lenimen Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pazhangat Nazar, Shahid Manthedath, Abdul Shibili, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232KL2014PTC036433
- Company No.
036433
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Mar 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Lenimen Biotech Private Limited offer?
Lenimen Biotech Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Anti Ulcer Drugs.
Who are the key members and board of directors at Lenimen Biotech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pazhangat Nazar  | Managing Director | 18-Mar-2014 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shahid Manthedath | Director | 18-Mar-2014 | Current |
| Abdul Shibili | Director | 18-Mar-2014 | Current |
| Midhul Nair | Director | 18-Mar-2014 | Current |
| Saji Subrahmanyan | Director | 08-Apr-2019 | Current |
Financial Performance and Corporate Structure Insights of Lenimen Biotech.
Lenimen Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 45.89% increase. The company also saw a substantial improvement in profitability, with a 12.03% increase in profit. The company's net worth Soared by an impressive increase of 32.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lenimen Biotech?
In 2020, Lenimen Biotech had a promoter holding of 86.00% and a public holding of 14.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lenimen Biotech?
Lenimen Biotech has a workforce of 10 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lenimen Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lenimen Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
